This week J&J held their Pharma business investor call, and the below data points are highlighting why J&J holds a superior pharmaceutical portfolio:
· Over 350 R&D programs, with $8.4B invested in 2017
· 14 new products approved since 2011, industry leader in brands over $1B in sales
· 100% of its operational growth comes from volume (not price increase)
· 10 new filings and/or launches anticipated between 2017-2021, each expecting >$1B in sales
[tag JNJ]
$JNJ.US
Julie S. Praline
Director, Equity Analyst
Direct: 617.226.0025
Fax: 617.523.8118
Crestwood Advisors
One Liberty Square
Suite 500
Boston, MA 02109